[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 85
Citations 0
Editor's Correspondence
Feb 13, 2012

Experience Is a Gloomy Lantern That Does Not Even Illuminate Its Bearer

Author Affiliations

Author Affiliation: Department of Public Health, Gres, Amiens, France.

Arch Intern Med. 2012;172(3):294. doi:10.1001/archinternmed.2011.760

Steinman1 stressed that millions of people were early adopters of rofecoxib (Vioxx; Merck Co) and rosiglitazone (Avandia; GlaxoSmithKline), which were withdrawn or restricted for severe safety concerns. Accordingly, the findings of Schwartz and Woloshin2 are very surprising. They showed evidence that a substantial proportion of the public mistakenly believes that the Food and Drug Administration approves only extremely effective drugs and drugs lacking serious adverse effects.2 This deserves 2 questions.

First Page Preview View Large
First page PDF preview
First page PDF preview